Skip to content

The study regarding effectiveness of Khadiradi Ghanavati in Diabetic patients

The critical exposition of nidana-dosha-dushya of Prameha Roga as described in Brihattrayi and clinical study of Khadira-Kramuka Kashaya Ghanavati in cases of Kshaudrameha

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012823
Enrollment
60
Registered
2018-03-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Khadira-Kramuka Kashaya Ghanavati: 500 mg pill manufactured by reducing aqueous decoction of Khadira (extract of Acacia catechu) and Kramuka (fruit of Areca catechu)
twice a day before meals for a period of 90 days. Control Intervention1: Nisha-Aamalaki-Shilajatu Yoga: A combination of dry powder of Nisha (Curcuma longa) and Aamalaki (Emblica officinalis) 3 g each
twice a day before meals for a period of 90 days.

Sponsors

Department of Samhita and Sanskrit
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The newly diagnosed cases as well as the patients under oral medication having fasting blood glucose level 126 mg/dl to 200 mg/dl or 2-hour plasma glucose level 200 mg/dl to 300 mg/dl and HbA1c% level between 6.5 to 8.5%.

Exclusion criteria

Exclusion criteria: 1. Patients below 25 years and above 60 years. 2. Patients having FBS 200 mg/dl and PPBS 300 mg/dl. 3. Patients having HbA1C% 8.5%. 4. All patients of diabetes mellitus receiving insulin. 5. Patients having chronic complications of diabetes mellitus like â?? a. Micro vascular: Retinopathy, neuropathy & nephropathy b. Macro vascular: Coronary Artery Disease, Peripheral vascular disease and cerebrovascular disease

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of trial drug with respect to symptomatic improvement (Grade 0 - absent, Grade 1-3 - Increasing severity)Timepoint: 3 months

Secondary

MeasureTime frame
To evaluate the efficacy of trial drug with respect to blood glucose levels (fasting & post prandial) and glycated Hb levelTimepoint: 3 months

Countries

India

Contacts

Public ContactDr Ajai Kumar Pandey

Institute of medical sciences

varunx78@gmail.com8808979442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026